Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 21, 2023

Investigational Drug Information for Ortataxel

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

What is the development status for investigational drug Ortataxel?

Ortataxel is an investigational drug.

There have been 4 clinical trials for Ortataxel. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1^st 2002.

The most common disease conditions in clinical trials are Lymphoma, Glioblastoma, and Lung Neoplasms. The leading clinical trial sponsors are Theradex, National Cancer Institute (NCI), and Roswell Park Cancer Institute.

Summary for Ortataxel

US Patents	0
International Patents	0
US Patent Applications	2,134
WIPO Patent Applications	1,379
Japanese Patent Applications	533
Clinical Trial Progress	Phase 2 (2002-01-01)
Vendors	17

Recent Clinical Trials for Ortataxel

Title	Sponsor	Phase
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma	Mario Negri Institute for Pharmacological Research	Phase 2
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer	National Cancer Institute (NCI)	Phase 2
BAY 59-8862 in Treating Patients With Non-Small Cell Lung Cancer	Roswell Park Cancer Institute	Phase 2

See all Ortataxel clinical trials

Clinical Trial Summary for Ortataxel

Top disease conditions for Ortataxel

Top clinical trial sponsors for Ortataxel

See all Ortataxel clinical trials

US Patents for Ortataxel

+ Get email alerts for changes to this table

Subscribe to access the full database, or Try a Trial
Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
>Drugname	>Patent Number	>Patent Title	>Patent Assignee	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Dow

Baxter

Boehringer Ingelheim

Express Scripts

Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.